Food and Drug Administration Revitalization Act

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jphill19 (talk | contribs) at 19:47, 14 April 2024 (Content Revised ~ Reference Specified). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Food and Drug Administration Revitalization Act
Great Seal of the United States
Long titleAn Act to amend the Federal Food, Drug, and Cosmetic Act to revitalize the Food and Drug Administration, and for other purposes.
Enacted bythe 101st United States Congress
EffectiveNovember 28, 1990
Citations
Public law101-635
Statutes at Large104 Stat. 4583
Codification
Acts amendedFederal Food, Drug, and Cosmetic Act
Titles amended21 U.S.C.: Food and Drugs
U.S.C. sections amended
Legislative history

The Food and Drug Administration Revitalization Act was introduced by the 101st Congress of the United States. Senator Orrin G. Hatch was the chairperson sponsor of the federal revitalization amendment for the Food and Drug Administration.

The FDA revitalization was orchestrated by Commissioner of Food and Drugs Dr. David Kessler in pursuant of the authorization;[1]

  • Enforcement procedures streamlined by contingencies of FDA regulatory field activities
  • Establishment of Office of Criminal Investigations
  • Progressive domestic and imports investigation programs by FDA[2]
  • Reduction in application review times for public healthcare products
  • Safety information and adverse event reporting program ― MedWatch
  • Standardization of nutrition facts label for human consumption products
  • Information technology transformation harmonizing FDA as an information agency

The Title 21 amendment was signed into law on November 28, 1990, by the 43rd President of the United States George H. W. Bush.

Provisions of the Act

The Food and Drug Administration Revitalization Act of 1990 was penned with four legislative titles establishing a medium for the rejuvenation of the public health agency.

Title I: Administrative and Laboratory Facility Consolidation - 21 U.S.C. § 379b

General Services Administration provided authority to grant contracts for consolidated Food and Drug Administration facilities. The contracts shall be granted for the design, construction, and operation of consolidated Food and Drug Administration facilities.

Title II: Recovery and Retention of Fees for FOIA Requests - 21 U.S.C. § 379c

Charge fees shall be applied to recover reasonable costs incurred in processing Freedom of Information requests for records obtained or created under this Act.

Title III: Scientific Review Groups - 21 U.S.C. § 394

Technical and scientific review groups shall be established as needed to perform functions of the Food and Drug Administration.

Title IV: Automation of FDA - 21 U.S.C. § 379d

Agency shall automate appropriate activities of the Food and Drug Administration to ensure timely review of regulatory activities under this Act.

References

  1. ^ Kessler, David A (May 1991). "Responding to the Challenge: A Revitalized FDA". Food, Drug, Cosmetic Law Journal. 46 (3). Food and Drug Law Institute: 391–394. JSTOR 26659032.
  2. ^ Williams, Jr., Troy E (February 1992). "FDA Investigators and Investigations in the 1990s". Food and Drug Law Journal. 47 (3). Food and Drug Law Institute: 279–286. JSTOR 26659216.

Observations of U.S. Government Accountability Office

External links